<main role="main" class="html-publication" lang="en">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a href="/government/organisations/department-of-health-and-social-care" class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color">
      <span class="gem-c-organisation-logo__name">Department<br>of Health &amp;<br>Social Care</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>

  
  <h1 class="gem-c-title__text govuk-heading-xl">
    National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 11 October 2021</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav class="gem-c-contents-list" aria-label="Contents" data-module="gem-track-click" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a href="#high-level-process" data-track-category="contentsClicked" data-track-label="#high-level-process" data-track-action="content_item 1" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-options="{&quot;dimension29&quot;:&quot;High-level process&quot;}">High-level process</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" data-track-label="#registering-interest" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 2" data-track-options="{&quot;dimension29&quot;:&quot;Registering interest&quot;}" href="#registering-interest">Registering interest</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-action="content_item 3" data-track-options="{&quot;dimension29&quot;:&quot;Triage&quot;}" href="#triage" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked" data-track-label="#triage">Triage</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;Initial review of offers&quot;}" href="#initial-review-of-offers" data-track-category="contentsClicked" data-track-action="content_item 4" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#initial-review-of-offers">Initial review of offers</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;Technical validation and in-service evaluation&quot;}" href="#technical-validation-and-in-service-evaluation" data-track-action="content_item 5" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked" data-track-label="#technical-validation-and-in-service-evaluation">Technical validation and in-service evaluation</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-action="content_item 6" data-track-label="#review-by-the-technical-validation-group" href="#review-by-the-technical-validation-group" data-track-options="{&quot;dimension29&quot;:&quot;Review by the Technical Validation Group&quot;}" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked">Review by the Technical Validation Group</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;Procurement&quot;}" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#procurement" href="#procurement" data-track-action="content_item 7" data-track-category="contentsClicked">Procurement</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" data-track-action="content_item 8" data-track-label="#products-in-the-pipeline-tvg" data-track-options="{&quot;dimension29&quot;:&quot;Products in the pipeline (TVG)&quot;}" href="#products-in-the-pipeline-tvg" class="gem-c-contents-list__link govuk-link govuk-link--no-underline">Products in the pipeline (TVG)</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-options="{&quot;dimension29&quot;:&quot;Publication of results&quot;}" href="#publication-of-results" data-track-action="content_item 9" data-track-label="#publication-of-results">Publication of results</a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button data-module="print-link" class="govuk-link govuk-body-s gem-c-print-link__button">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png" class="print-meta-data-licence">
</p>
<p>
  Â© Crown copyright 2021
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/coronavirus-covid-19-serology-and-viral-detection-testing-uk-procurement-overview
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div data-module="govspeak" class="gem-c-govspeak govuk-govspeak ">
    
    
      <div class="govspeak">
<div role="note" aria-label="Information" class="application-notice info-notice">
<p>This guidance only applies to SARS-CoV-2 (COVID-19) viral detection and antigen tests.</p>
</div>

<p>This guidance outlines how the government will triage, review and evaluate offers of viral detection, antigen and antibody tests to support the National Test and Trace programme.</p>

<p>For any non-machine based <abbr title="Lateral Flow Technology">LFT</abbr> and home testing kits, an <a href="https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/protocol-for-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices" class="govuk-link">alternative technical validation route</a> will be required.</p>

<p>For all antibody tests, an alternative technical validation route will be required.</p>

<p>Whether or not a test developer or supplier explores national-level procurement via this process, they are still able to supply tests with the relevant regulatory authorisation to UK customers.</p>

<h2>High-level process</h2>

<p>The technical validation process involves 6 keys steps:</p>

<ol>
  <li>Register through the online form</li>
  <li>Triage of online form by scientific advisor</li>
  <li>Initial review by Scientific Expert Panel</li>
  <li>Technical and in-service evaluation</li>
  <li>Decision by the Technical Validation Group</li>
  <li>Procurement discussion<sup role="doc-noteref"><a class="govuk-link" href="#fn:1" rel="footnote">[footnote 1]</a></sup>
</li>
</ol>

<h2>Registering interest</h2>
<p>Manufacturers of SARS-CoV-2 (COVID-19)  tests for viral detection, antigen and antibody tests can register their interest in the national procurement process if their test meets, or are intended to meet in the case of tests under development, the requirements of a relevant <a href="https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work" class="govuk-link">Medicines and Healthcare products Regulatory Agency (<abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>) Target Product Profiles (<abbr title="target product profiles">TPPs</abbr>)</a>.</p>

<p>Antigen test manufacturers are invited to complete the <a href="https://support-covid-19-testing.dhsc.gov.uk/Full-Test-Kit-Covid19" rel="external" class="govuk-link">online form</a> for each test they want to supply. The form captures the main clinical and commercial information required to triage the large volume of offers received.</p>

<p>Antibody test manufacturers are invited to join the <a class="govuk-link" rel="external" href="https://health-family-contract-search.secure.force.com/ProSpend__CS_ContractPage?SearchType=Projects&amp;uid=a074J000007FUgJQAW&amp;searchStr=&amp;sortStr=Recently+Published&amp;page=1&amp;filters=">Dynamic Purchasing System (DPS) for antibody devices</a>. Please note that joining the Dynamic Purchasing System does not guarantee that any orders will be placed with a supplier and is not a contract to provide goods to the department. Only once an invitation is issued and awarded will a contract be formed. It will only cover the specific requirement needed by that invitation.</p>

<p>Antibody test manufacturers are invited to seek independent evaluation of their tests. See the <a href="https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/national-standardised-test-performance-process-for-manufacturers-of-sars-cov-2-virus-antibody-tests" class="govuk-link">national standardised test performance process</a> for more information.</p>

<p>As part of our commitment to acquiring high-quality products for the National Test and Trace programme, information should be provided directly from the test manufacturers. This ensures that the technical information can be confirmed directly with the manufacturer.</p>

<div role="note" class="application-notice help-notice" aria-label="Warning">
<p>If you have been contacted proactively by another government department who are already reviewing your offer, please do not complete an online form unless specifically requested to do so.</p>
</div>

<p>Further procurement opportunities that support the UK testing strategy set out by the Secretary of State for Health and Social Care, can be found on <a href="https://www.contractsfinder.service.gov.uk/" rel="external" class="govuk-link">Contracts finder</a>.</p>

<h2>Triage</h2>

<p>The online form submission and any supporting documents are reviewed by a scientific advisor to categorise the type of test and refer it through appropriate validation and evaluation route.</p>

<p>For all viral detection and antigen tests, excluding non-machine based Lateral Flow Technology (<abbr title="Lateral Flow Technology">LFT</abbr>) and home testing kits, the steps outlined below apply.</p>

<p>For any non-machine based <abbr title="Lateral Flow Technology">LFT</abbr> and home testing kits, an <a href="/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/protocol-for-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices" class="govuk-link">alternative technical validation route will be required</a>.</p>

<h2>Initial review of offers</h2>

<p>The online form and supporting documents are initially reviewed by a member of the Scientific Expert Group. The Scientific Expert Group is made up experts in technologies, viral testing and infectious disease. This a subgroup of the Technologies Validation Group (<abbr title="Technical Validation Group">TVG</abbr>). The Group undertakes a detailed assessment of the information on the solutions and technologies that have been submitted.</p>

<p>The initial review is based on a review of the clinical and technical information provided by the manufacturer against the <a href="https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work" class="govuk-link"><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> <abbr title="target product profiles">TPPs</abbr></a>. Following the review tests are deemed to be one of the following:</p>

<ul>
  <li>aligned to the current national testing priority needs and progressed for national validation and evaluation</li>
  <li>not aligned to the current national testing priority needs and held on file for review in case of any future changes to our testing needs</li>
  <li>not to currently have the performance and clinical data required to pass triage but where it is recommended that the organisation generates this data</li>
</ul>

<div class="application-notice help-notice" aria-label="Warning" role="note">
<p>Companies should expect to receive any outcome from the Scientific Expert Group within 2 weeks. This may be longer subject to the volume of offers that we are reviewing.</p>
</div>

<h2>Technical validation and in-service evaluation</h2>

<p>Offers that are deemed by the Scientific Expert Group to have met the relevant <abbr title="target product profile">TPP</abbr> and align to the current needs of the National Test and Trace programme will be progressed for technical validation and in-service evaluation. Manufacturers will be contacted and invited to take part in further technical validation and/or in-service evaluation.</p>

<p>As part of the technical validation process and/or in-service evaluation manufacturers will be matched with a validation laboratory. The manufacturer will be expected to:</p>

<ul>
  <li>provide product samples and all required consumables and reagents free of charge for validation and evaluation</li>
  <li>provide the laboratories undertaking the technical validation with additional relevant technical information to support the validation activity</li>
  <li>provide the relevant legal documents to support the technical validation and in-service evaluation, and non-disclosure agreements, where needed</li>
  <li>agree to the results of the process to be made publicly available</li>
  <li>confirm that they have immediate availability of sufficient testing kits to allow further in-service evaluation and can provide sufficient product volumes, including consumables and reagents, with a lead time less than one month from order</li>
</ul>

<h3>Technical validation</h3>

<p>The technical validation includes, but is not limited to, a bio-safety assessment, lower dynamic range analysis and an initial test accuracy assessment. The information generated at this stage will be compared to the <abbr title="target product profile">TPP</abbr>. Products that meet the technical validation criteria may progress to an in-service evaluation.</p>

<p>See further information about the <a href="/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/technical-validation-protocol-for-sars-cov-2-nucleic-acid-detection" class="govuk-link">technical validation protocol</a>.</p>

<h3>In-service evaluation (for example, hospitals and care homes)</h3>

<p>Tests will be performed by the intended user in the relevant setting to develop real-world evidence. This evaluation is tailored to the setting and the type of test. It typically includes consideration of installation (for example, does the equipment require specialist installation or calibration) and usability factors (for example, does the result require any interpretation and, if yes, how skilled does the user need to be to interpret the result?)</p>

<h2>Review by the Technical Validation Group</h2>

<p>The outcome of the technical validation and in-service evaluation will be reviewed by the Technical Validation Group (<abbr title="Technical Validation Group">TVG</abbr>).</p>

<p>The <abbr title="Technical Validation Group">TVG</abbr> includes a range of experts in technologies, viral testing and infectious disease, including representatives from the:</p>

<ul>
  <li>central validation labs (including Public Health England (<abbr title="Public Health England">PHE</abbr>), Frimley, Cumbria)</li>
  <li>
<abbr title="(COVID-19 National Diagnostic Research and Evaluation Platform)">CONDOR</abbr> (COVID-19 National Diagnostic Research and Evaluation Platform)</li>
  <li>Innovate UK</li>
  <li>academia professional body (Royal College of Pathology)</li>
  <li>Medicines and Healthcare products Regulatory Agency</li>
</ul>

<p>This group replaces all of the functions of the previous Viral Detection (molecular) Tests Group (<abbr title="Viral Detection Tests Advisory Group">VTAG</abbr>) and the for new serology technologies, the work previously undertaken by the New Tests Advisory Group (<abbr title="New Tests Advisory Group">NTAG</abbr>).</p>

<p><abbr title="Technical Validation Group">TVG</abbr> reviews the outcome of all of the validation and evaluations and makes recommendations to the wider COVID-19 TTCE programme on the suitability of the solutions/technologies.</p>

<h2>Procurement</h2>
<p>For those technologies recommended by the <abbr title="Technical Validation Group">TVG</abbr> that suit use cases with unmet demand, the <abbr title="Department of Health and Social Care">DHSC</abbr> commercial team will invite those developers or suppliers to take part in a competitive procurement either via mini-competition or via appropriate frameworks.</p>

<h2>Products in the pipeline (<abbr title="Technical Validation Group">TVG</abbr>)</h2>

<p>The following table provides a snapshot of the number of products currently in <abbr title="Technical Validation Group">TVG</abbr> pipeline (as at 14 June 2021) and their status:</p>

<h3>Validation stage</h3>

<table>
  <thead>
    <tr>
      <th scope="col">Status</th>
      <th scope="col" style="text-align: right">Number of tests</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>In early stages of validation</td>
      <td style="text-align: right">11</td>
    </tr>
    <tr>
      <td>Currently being validated or evaluated</td>
      <td style="text-align: right">4</td>
    </tr>
    <tr>
      <td>Validation concluded or paused</td>
      <td style="text-align: right">108</td>
    </tr>
    <tr>
      <td>Validated technology</td>
      <td style="text-align: right">19</td>
    </tr>
    <tr>
      <td>Total</td>
      <td style="text-align: right">142</td>
    </tr>
  </tbody>
</table>

<h3>Validation concluded or paused</h3>

<p>The âProducts in the pipeline (<abbr title="Technical Validation Group">TVG</abbr>): validation concluded or pausedâ table is on the main <a class="govuk-link" href="https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests">Assessment and procurement of coronavirus (COVID-19) tests page</a>.</p>

<h2>Publication of results</h2>

<p>The following technologies have been reviewed:</p>

<ul>
  <li><a rel="external" href="https://www.medrxiv.org/content/10.1101/2020.04.15.20066407v2" class="govuk-link">ELISA (enzyme-linked immunosorbent assay) assessments</a></li>
  <li><a class="govuk-link" href="https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results">first wave of lateral flow test and non-machine based <abbr title="Lateral Flow Technology">LFT</abbr> assessment</a></li>
  <li><a class="govuk-link" href="https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results">first wave of lateral flow test assessments</a></li>
  <li><a class="govuk-link" href="https://www.gov.uk/government/publications/covid-19-phe-laboratory-assessments-of-molecular-tests">first wave of laboratory assessments of molecular tests</a></li>
</ul>

<h3>Validated technology</h3>

<p><a class="govuk-link" href="https://www.gov.uk/government/publications/coronavirus-covid-19-serology-and-viral-detection-tests-technical-validation-reports">Read the validation reports</a> for each of these products.</p>

<p>The performance results are based on the specific assay version described in the validation reports. Subsequent changes to the assay may result in deviation from these results and therefore the product will need to be locally verified for consistency as part of routine deployment.</p>

<table>
  <thead>
    <tr>
      <th scope="col">   Company</th>
      <th scope="col">   Product</th>
      <th scope="col">  Format</th>
      <th style="text-align: right" scope="col">  Limit of detection</th>
      <th scope="col" style="text-align: right">  Sensitivity</th>
      <th scope="col" style="text-align: right"> Specificity</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th scope="row"> Optigene</th>
      <td>GenieÂ® HT and GenieÂ®   III</td>
      <td>RNA RT-<abbr title="loop-mediated isothermal amplification">LAMP</abbr> on swabs</td>
      <td style="text-align: right">1,000 copies/ml</td>
      <td style="text-align: right">97% (<abbr title="confidence interval">CI</abbr> 93% to 99%)</td>
      <td style="text-align: right">99% (<abbr title="confidence interval">CI</abbr> 99% to 100%)</td>
    </tr>
    <tr>
      <th scope="row">   Optigene</th>
      <td>GenieÂ® HT and GenieÂ®   III</td>
      <td>RNA RT-<abbr title="loop-mediated isothermal amplification">LAMP</abbr> on saliva</td>
      <td style="text-align: right">1,000 copies/ml</td>
      <td style="text-align: right">82% (<abbr title="confidence interval">CI</abbr> 68% to 91%)</td>
      <td style="text-align: right">100% (<abbr title="confidence interval">CI</abbr> 99% to 100%)</td>
    </tr>
    <tr>
      <th scope="row">  Optigene</th>
      <td>GenieÂ® HT and GenieÂ®   III</td>
      <td>Direct RT-<abbr title="loop-mediated isothermal amplification">LAMP</abbr> on swabs</td>
      <td style="text-align: right">1,000 copies/ml</td>
      <td style="text-align: right">72% (<abbr title="confidence interval">CI</abbr> 64% to 78%)</td>
      <td style="text-align: right">100% (<abbr title="confidence interval">CI</abbr> 99% to 100%)</td>
    </tr>
    <tr>
      <th scope="row">  Optigene</th>
      <td>GenieÂ® HT and GenieÂ®   III</td>
      <td>Direct RT-<abbr title="loop-mediated isothermal amplification">LAMP</abbr> on saliva</td>
      <td style="text-align: right">1,000 copies/ml</td>
      <td style="text-align: right">80% (<abbr title="confidence interval">CI</abbr> 72% to 85%)</td>
      <td style="text-align: right">100% (<abbr title="confidence interval">CI</abbr> 98% to 100%)</td>
    </tr>
    <tr>
      <th scope="row">  Diagnostics for the Real World</th>
      <td>SAMBA II SARS-COV-2 Test</td>
      <td>
<abbr title="point of care test">POCT</abbr> combined extraction and RT-PCR</td>
      <td style="text-align: right">250 copies/ml</td>
      <td style="text-align: right">98.8% (<abbr title="confidence interval">CI</abbr> 95%)</td>
      <td style="text-align: right">100% (<abbr title="confidence interval">CI</abbr> 95%)</td>
    </tr>
    <tr>
      <th scope="row">   LGC Group Ltd</th>
      <td>End- point PCR (EPCR)</td>
      <td>Extracted RT-PCR with endpoint detection</td>
      <td style="text-align: right">50 copies/ml</td>
      <td style="text-align: right">98.68% (<abbr title="confidence interval">CI</abbr> 97.86% to 99.24%)</td>
      <td style="text-align: right">98.56% (<abbr title="confidence interval">CI</abbr> 97.55% to 99.23%)</td>
    </tr>
    <tr>
      <th scope="row">  Horiba</th>
      <td>POCKITâ¢</td>
      <td>Central Nucleic Acid Analyzer</td>
      <td style="text-align: right">2440 copies/ml</td>
      <td style="text-align: right">95.75% (95% <abbr title="confidence interval">CI</abbr> 91.0%  to 98.1%)</td>
      <td style="text-align: right">97.7% (95% <abbr title="confidence interval">CI</abbr> 95.2 to 99.0%)</td>
    </tr>
    <tr>
      <th scope="row"> QuantuMDx</th>
      <td>SARS-CoV-2 Nucleic Acid Detection</td>
      <td>RT-PCR</td>
      <td style="text-align: right">500 copies/ml</td>
      <td style="text-align: right">98.9% (97.1 to 99.6)</td>
      <td style="text-align: right">99.1% (97.6 to 99.6)</td>
    </tr>
    <tr>
      <th scope="row"> Oxford Nanopore</th>
      <td>LamPORE</td>
      <td>RNA RT-qPCR</td>
      <td style="text-align: right">20 copies/ml</td>
      <td style="text-align: right">99.57%   (95% <abbr title="confidence interval">CI</abbr> 98.46 to 99.99%)</td>
      <td style="text-align: right">99.40%   (95% <abbr title="confidence interval">CI</abbr> 99.28 to 99.50%)</td>
    </tr>
    <tr>
      <th scope="row"> Nonacus</th>
      <td>VirPath Sars-CoV-2 Multiplex qRT-PCR</td>
      <td>qRT-PCR</td>
      <td style="text-align: right">250 to 500 copies/ml</td>
      <td style="text-align: right">98.40% (95.34% to 99.45%)</td>
      <td style="text-align: right">98.90% (97.70% to 99.65%)</td>
    </tr>
    <tr>
      <th scope="row"> Abbott</th>
      <td>ID Now</td>
      <td>Direct Isothermal Assay</td>
      <td style="text-align: right">&lt;1000 copies/ml</td>
      <td style="text-align: right">Nasal Swabs 89.5% (95% <abbr title="confidence interval">CI</abbr> 83.2 to 93.7%), Nasopharyngeal 93.2% (85% <abbr title="confidence interval">CI</abbr> 84.3 to 97.5%)</td>
      <td style="text-align: right">Nasal Swabs 98.4% (95% <abbr title="confidence interval">CI</abbr> 96.5 to 99.3%), Nasopharyngeal 98.1% (95% <abbr title="confidence interval">CI</abbr> 95.7 to 99.2%)</td>
    </tr>
    <tr>
      <th scope="row">  LumiraDx</th>
      <td>
<abbr title="point of care">POC</abbr>   rapid COVID-19 Ag test</td>
      <td><abbr title="point of care">POC</abbr></td>
      <td style="text-align: right">~62500 copies/ml     Claimed 32 TCID 50/ml</td>
      <td style="text-align: right">83.8 (95% <abbr title="confidence interval">CI</abbr> 76.4 to 89.2%).</td>
      <td style="text-align: right">98.7% (95% <abbr title="confidence interval">CI</abbr> 97.2 to 99.4%).</td>
    </tr>
    <tr>
      <th scope="row"> Primer   Design Ltd</th>
      <td>PROmate</td>
      <td>Direct qRT-PCR</td>
      <td style="text-align: right">960   copies/ml</td>
      <td style="text-align: right">91.3%   (95% <abbr title="confidence interval">CI</abbr> 87.1 to 94.3)</td>
      <td style="text-align: right">99.0%   (95% <abbr title="confidence interval">CI</abbr> 97.8 to 99.6)</td>
    </tr>
    <tr>
      <th scope="row"> DNA Nudge</th>
      <td>DNA Nudge</td>
      <td>
<abbr title="point of care">POC</abbr> (non-extracted) RT-PCR</td>
      <td style="text-align: right">5000 copies/ml</td>
      <td style="text-align: right">82.1% (95% <abbr title="confidence interval">CI</abbr> 77.7 to 85.7)*</td>
      <td style="text-align: right">99.1% (95% <abbr title="confidence interval">CI</abbr> 98.4-99.5%</td>
    </tr>
    <tr>
      <th scope="row"> Certest Biotech</th>
      <td>Viasure</td>
      <td>qRT-PCR</td>
      <td style="text-align: right">&lt;1000 copies/ml (20 genome copies per reaction)</td>
      <td style="text-align: right">99% (95% <abbr title="confidence interval">CI</abbr> 96 to 99%)</td>
      <td style="text-align: right">100% (95% <abbr title="confidence interval">CI</abbr> 98 to 100%)</td>
    </tr>
    <tr>
      <th scope="row"> Randox</th>
      <td>Rapid PCR</td>
      <td>PCR</td>
      <td style="text-align: right">725 copies/ml</td>
      <td style="text-align: right">99% (95% <abbr title="confidence interval">CI</abbr> 96 to 99%)</td>
      <td style="text-align: right">100% (95% <abbr title="confidence interval">CI</abbr> 99 to 100%)</td>
    </tr>
    <tr>
      <th scope="row"> Thermo Fisher</th>
      <td>Taqpath</td>
      <td>PCR</td>
      <td style="text-align: right">250 GCE/ml</td>
      <td style="text-align: right">100% (95% <abbr title="confidence interval">CI</abbr> 98 to 100%)</td>
      <td style="text-align: right">100% (95% <abbr title="confidence interval">CI</abbr> 99 to 100%)</td>
    </tr>
    <tr>
      <th scope="row"> BD Veritor</th>
      <td>BD Veritorâ¢ System</td>
      <td><abbr title="point of care">POC</abbr></td>
      <td style="text-align: right">1.4 x 102 TCID50/ml</td>
      <td style="text-align: right">85.2% (95% <abbr title="confidence interval">CI</abbr> 79.1 to 89.8)</td>
      <td style="text-align: right">98.4% (95% <abbr title="confidence interval">CI</abbr> 96.2 to 99.4)</td>
    </tr>
    <tr>
      <th scope="row"> VMD Health (UK) and Alveo Technologies Inc</th>
      <td>be.wellâ¢</td>
      <td><abbr title="point of care">POC</abbr></td>
      <td style="text-align: right">&lt;100copies/ml</td>
      <td style="text-align: right">95.3% (95% <abbr title="confidence interval">CI</abbr> 90.6 to 97.8)</td>
      <td style="text-align: right">97.0% (95% <abbr title="confidence interval">CI</abbr> 94.5 to 98.4)</td>
    </tr>
    <tr>
      <th scope="row">Roche Cobas</th>
      <td>SARS CoV-2</td>
      <td>Extracted RT-PCR</td>
      <td style="text-align: right">50 copies/mL</td>
      <td style="text-align: right">99.4% (95% Cl 96.5 to 99.9)</td>
      <td style="text-align: right">100% (95% Cl 97.8 to 99.9)</td>
    </tr>
    <tr>
      <th scope="row">Roche Cobas Liat</th>
      <td>SARS CoV-2 + Influenza A/B</td>
      <td>Extracted RT-PCR</td>
      <td style="text-align: right">50 copies/mL</td>
      <td style="text-align: right">97.6% (95% <abbr title="confidence interval">CI</abbr> 94.1 to 99.1)</td>
      <td style="text-align: right">99.2% (95% <abbr title="confidence interval">CI</abbr> 98.4 to 99.6)</td>
    </tr>
  </tbody>
</table>

<p>*There is a range of sensitivities across validation sites. Please see the full report.</p>

<p>Other technologies that have been validated will be added to the table once the manufacturer has consented to publication.</p>

<div role="doc-endnotes" class="footnotes">
  <ol>
    <li role="doc-endnote">
      <p>Commercial and supply chain conversations will commence earlier in the process and happen in parallel through the relevant process.&nbsp;<a class="govuk-link" role="doc-backlink" href="#fnref:1" aria-label="go to where this is referenced">â©</a></p>
    </li>
  </ol>
</div>
</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a href="#contents" class="govuk-link app-c-back-to-top dont-print">
    <svg height="17" width="13" focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 13 17" class="app-c-back-to-top__icon">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>